No connection

Search Results

GRDN vs LFST

GRDN
Guardian Pharmacy Services, Inc.
BEARISH
Price
$37.93
Market Cap
$2.44B
Sector
Healthcare
AI Confidence
85%
LFST
LifeStance Health Group, Inc.
NEUTRAL
Price
$6.40
Market Cap
$2.45B
Sector
Healthcare
AI Confidence
80%

Valuation

P/E Ratio
GRDN
48.63
LFST
320.0
Forward P/E
GRDN
28.13
LFST
16.74
P/B Ratio
GRDN
11.67
LFST
1.63
P/S Ratio
GRDN
1.68
LFST
1.72
EV/EBITDA
GRDN
23.32
LFST
34.04

Profitability

Gross Margin
GRDN
20.21%
LFST
32.37%
Operating Margin
GRDN
8.89%
LFST
4.74%
Profit Margin
GRDN
3.4%
LFST
0.68%
ROE
GRDN
26.61%
LFST
0.65%
ROA
GRDN
13.68%
LFST
0.73%

Growth

Revenue Growth
GRDN
17.4%
LFST
17.4%
Earnings Growth
GRDN
--
LFST
--

Financial Health

Debt/Equity
GRDN
0.21
LFST
0.31
Current Ratio
GRDN
1.38
LFST
1.65
Quick Ratio
GRDN
1.04
LFST
1.38

Dividends

Dividend Yield
GRDN
--
LFST
--
Payout Ratio
GRDN
0.0%
LFST
0.0%

AI Verdict

GRDN BEARISH

GRDN presents a stark divergence between fundamental value and market price, with a Piotroski F-Score of 4/9 indicating only stable financial health. The stock is trading at a massive premium, with a current price of $37.93 compared to a Graham Number of $7.55 and an Intrinsic Value of $5.46. While growth metrics and analyst recommendations are strongly bullish, they are heavily offset by aggressive insider selling totaling over $419 million. The combination of extreme overvaluation and bearish insider sentiment outweighs the current growth trajectory.

Strengths
Strong ROE (26.61%) and ROA (13.68%) indicating efficient asset utilization
Low Debt/Equity ratio (0.21) suggesting a conservative leverage profile
Robust Q/Q earnings growth of 75.20% and YoY EPS growth of 54.2%
Risks
Severe overvaluation relative to deterministic benchmarks (Graham/Intrinsic)
Massive insider liquidation ($419.26M sold) by CEO, CFO, and Directors
Very low net profit margin (3.40%) leaving little room for operational error
LFST NEUTRAL

LFST presents a stable but precarious financial profile with a Piotroski F-Score of 4/9 and no Altman Z-Score provided for bankruptcy risk assessment. While the company has successfully transitioned toward profitability with a promising forward P/E of 16.74, it trades at a massive premium compared to its Graham Number ($1.33) and Intrinsic Value ($0.14). Strong revenue growth of 17.4% is offset by razor-thin profit margins (0.68%) and aggressive insider selling totaling $32.51M. The stock is currently a speculative play on earnings expansion rather than a value-driven investment.

Strengths
Low Debt/Equity ratio of 0.31 indicating manageable leverage
Consistent revenue growth of 17.4% YoY and Q/Q
Successful transition from historical losses to positive EPS
Risks
Extreme trailing P/E ratio of 320.00
Heavy insider selling totaling $32.51M in the last 6 months
Razor-thin net profit margins of 0.68%

Compare Another Pair

GRDN vs LFST: Head-to-Head Comparison

This page compares Guardian Pharmacy Services, Inc. (GRDN) and LifeStance Health Group, Inc. (LFST) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile